explore -WSS

explore

author：Wikipedia 2025-09-30 17:43:55 - browse：785

Humana’s Medicare Advantage enrollees got care in the hospital and physician clinics way more often than the company predicted at the end of 2023, forcing the health insurance giant on Thursday to drastically slash its profit projections for both 2023 and 2024.

Those higher medical costs will wipe away more than $775 million of profit that Humana had expected to bank for 2023. Humana also is “currently assessing the expected impact of emerging utilization trends on its 2024 outlook, which is anticipated to be material if current trends continue,” according to the company’s update to investors.

Humana’s bad news for Wall Street didn’t end there: The company said it appears it only added just 100,000 new Medicare Advantage members from the most recent enrollment period that ended last month — down from estimates that it would enroll anywhere from 325,000 to 435,000 people.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Readout Newsletter: The latest on Amylyx, Moderna, Novavax

hotspot

WSS

Lack of health data on LGBTQ+ people has serious consequences

Ohio train derailment: Experts on toxic chemical risks

CDC advisory group OKs chikungunya vaccine

Childhood vaccination ad campaign launches in the U.K.

Study fuels hope CAR

CDC panel: People 65 and older should get a Covid spring booster shot

leisure time

explore

hotspot

Guidelines to prevent youth baseball injuries need more muscle

Childhood vaccination ad campaign launches in the U.K.

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Doctor of U.S. President Joe Biden says he is fit for duty

Sports medicine is finally prioritizing gender equality

Using force crossed my mind when examining a defiant young patient

Trump demands the U.S. pay no more for drugs than other countries … again

Medicare drug price negotiation continues, as pharma counteroffers

Cancer drug shortages should be causing more outrage

Ohio train derailment: Experts on toxic chemical risks

leisure time

CDC advisory group OKs chikungunya vaccine

Are embryos people? Reproductive medicine's future depends on the answer

Microsoft's Peter Lee: Generative AI could help doctors be more human

Families look for replacement for GSK asthma drug Flovent

Stem cell biologist probes earliest stages of human development

Stem cell biologist probes earliest stages of human development

focus

leisure time

hotspot

focus